Jason Luke, MD: The Impact of BRAF/MEK Inhibitors in Melanoma
What impact have BRAF/MEK inhibitors had, since their initial approval, and how has this changed mutation testing for melanoma?
CASE: Metastatic Melanoma
Charles, a 62-year-old Caucasian landscaper, presented to his primary care physician with fatigue, dyspnea upon exertion, and a nonproductive cough that has lasted for 6 to 8 weeks. .
- Following a medical examination, a suspicious mole was biopsied, which resulted in a diagnosis of melanoma.
- Genetic testing revealed aBRAFV600K mutation
- PET/CT scan shows metastases to the lung and a soft tissue nodule in the liver (1.4 cm x 1.1 cm)
- LDH levels and liver function test results were normal
- The patient’s ECOG performance status was 1
Treatment was initiated with the combination of BRAF and MEK inhibitors.
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More
Dosing and Regimen Changes Promote Tolerability in Advanced Melanoma
March 14th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.
Read More
